Showing 2231-2240 of 4063 results for "".
- Oculis Completes Enrollment in Both DIAMOND Phase 3 Trials of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-dme/2482732/Oculis Holding said it has completed enrollment in both phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME. The trials are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by t
- Iantrek Announces Positive Efficacy and Safety Profile of its Bio-Interventional Technologyhttps://modernod.com/news/iantrek-announces-positive-efficacy-and-safety-profile-of-its-bio-interventional-technology-to-enhance-uveoscleral-outflow-in-glaucoma-patients/2482707/Iantrek Corporation today announced positive results from its 2-year prospective clinical study evaluating its bio-reinforced cyclodialysis technology. The study, published in Ophthalmology Science, affirms the safety and efficacy of Iantrek’s bio-interventional technology to enhance&n
- Experimental Stem Cell Treatment Shows Success in Restoring Corneashttps://modernod.com/news/experimental-stem-cell-treatment-shows-success-in-restoring-corneas/2482700/A clinical trial testing an stem cell treatment for blinding cornea injuries has shown promising results. The expanded phase 1/2 trial, published in Nature Communications[1] found the treatment to be feasible and safe for 14 pa
- Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolaminehttps://modernod.com/news/opus-genetics-announces-fda-fast-track-and-enrollment-updates-for-phentolamine-ophthalmic-solution/2482681/Opus Genetics announced completion of enrollment in the VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. Opus also announced that enrollment in the LYNX-2 pivotal phase 3 trial, evaluating phentolamine for the treat
- FDA Clears ViGeneron's IND for Novel mRNA Gene Therapy to Treat Stargardt Disease and Other Retinal Dystrophieshttps://modernod.com/news/fda-clears-vigenerons-ind-for-novel-mrna-trans-splicing-gene-therapy-vg801-to-treat-stargardt-disease-and-other-abca4-linked-retinal-dystrophies/2482585/ViGeneron announced that the FDA has cleared the investigational new drug (IND) application for the phase 1/2 study of VG801, a gene therapy candidate to treat Stargardt disease and other retinal dystrophies associated with mutations in the&n
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely
- Ocugen Reports Positive Preliminary Data from OCU410 Trial for Geographic Atrophyhttps://modernod.com/news/ocugen-reports-positive-preliminary-data-from-ocu410-trial-for-geographic-atrophy/2482550/Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The trial, which includes nine patients across three dose cohorts, revealed promis
- FELIQS Receives FDA Fast Track Designation for FLQ-101, a First-in-Class Small Molecule to Prevent Retinopathy of Prematurityhttps://modernod.com/news/feliqs-receives-fda-fast-track-designation-for-flq-101-a-first-in-class-small-molecule-to-prevent-retinopathy-of-prematurity/2482526/FELIQS announced that the US Food and Drug Administration (FDA) has granted its lead asset, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Ja
- Ocuphire Publishes Phase 3 Trial Results of Ryzumvi for Reversal of Pharmacologically-Induced Mydriasishttps://modernod.com/news/ocuphire-publishes-phase-3-trial-results-of-ryzumvi-for-pharmacologically-induced-mydriasis-1/2482463/Ocuphire Pharma announced the full results from two pivotal phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of Ryzumvi (phentolamine ophthalmic solution 0.75%) for reversing pharmacologically-induced mydriasis. The data were
- Nanoscope Plans Phase 3 Trial of MCO-010 to Treat Stargardt Macular Degenerationhttps://modernod.com/news/nanoscope-plans-phase-3-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2482440/Nanoscope Therapeutics announced the completion of an End-of-phase 2 (EOP2) meeting with the FDA for its clinical program evaluating MCO-010 for the treatment of severe vision loss caused by Stargardt macular degeneration (SMD), supporting advancement of MCO-010 to a phase 3 registrational trial.